Study Design for a qualitative assessment of the implementation of the Asthma Navigator (Refer ID) tool in a Dutch primary care setting

05 Aug 2021
Respiratory conditions
  • Asthma
Type of resource
Abstract
Conference
Dublin 2021
Author(s)
Hans Wouters, General Practitioners Research Institute, Netherlands
Clinical Research Results Implementation Science/Service Development Research Ideas on Respiratory Conditions and Tobacco Dependency Abstract Research questions: What are the barriers and facilitators of the implementation of a novel E-health tool aimed at improving asthma visits and management?Background: Successful implementation of guidelines may result in better asthma management, and, if needed, in more appropriate and timely referrals to distinguish difficult-to-treat and severe asthma. The Asthma Navigator (or Refer ID tool) is a Web-based application that provides support to health care professionals during their pre-planned, in-person asthma review consultations by structured guidance through step-by-step questioning and capture of patient’s answers. The tool suggests to health care professionals how they may optimize patients’ asthma management or facilitate referral to asthma specialists, in accordance with best practice guidelines.Possible methodology: Before implementation, focus groups will be held with patients, health care professionals and policymakers about possible barriers and facilitators. This will be used to design the implementation plan. In a study setting, general practices will get familiar with the Asthma Navigator tool by using it during 10 consultations. Experiences of healthcare providers and patients will be collected using either interviews or questionnaires. Interviews and focus groups will be transcribed, coded and themes analysed.Questions to discuss: What are the key themes to discuss during the interviews? How can we apply the Standards for Reporting Implementation Studies (StaRI) Statement in this research? Declaration of Interest The global Refer ID Tool has been developed as part of the AstraZeneca PRECISION program in collaboration with Dr David Jackson, Prof Ricardo del Olmo, Dr Tan Tze Lee, Dr Mona Al Ahmad, Prof Janwillem Kocks. This independent implementation project in the NL is financially supported by AstraZeneca with an educational grant. Dr Kocks reports grants, personal fees and non-financial support from AstraZeneca, grants, personal fees and non-financial support from Boehringer Ingelheim, grants and personal fees from Chiesi Pharmaceuticals, grants, personal fees and non-financial support from GSK, grants and personal fees from Novartis, grants from MundiPharma, grants from TEVA, outside the submitted work. All personal fees are paid to the institutions. All the other authors declare that they have no competing interests. References and Clinical Trial Registry Information